Bone mineral content, cortical thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone decanoate, 1-alpha hydroxyvitamin D3, or intermittent calcium infusions

This publication has 12 references indexed in Scilit:

• Long-Term Estrogen Replacement Therapy Prevents Bone Loss and Fractures
  Annals of Internal Medicine, 1985
• Long-term treatment of postmenopausal osteoporosis with active vitamin D3, 1-alpha-hydroxycholecalciferol (1.ALPHA.-OHD3) and 1,24 dihydroxycholecalciferol (1,24(OH)2D3).
  Endocrinologia Japonica, 1985
• Bone Mineral and Calcium Metabolism Before, During and After Treatment of Osteoporosis with 1α-Hydroxyvitamin D3and Calcium
  Scandinavian Journal of Rheumatology, 1982
• BONE MASS IN POSTMENOPAUSAL WOMEN AFTER WITHDRAWAL OF OESTROGEN/GESTAGEN REPLACEMENT THERAPY
  The Lancet, 1981
• Decreased Risk of Fractures of the Hip and Lower Forearm with Postmenopausal Use of Estrogen
  New England Journal of Medicine, 1980
• Treatment of spinal osteoporosis in postmenopausal women.
  BMJ, 1980
• EFFECT ON BONE OF WITHDRAWAL OF ŒSTROGEN THERAPY
  The Lancet, 1979
• BONE RESPONSE TO TERMINATION OF ŒSTROGEN TREATMENT
  The Lancet, 1978
• Evaluation of intravenous calcium as therapy for osteoporosis
  The American Journal of Medicine, 1973